Interpace Diagnostics Group (NASDAQ:IDXG) has been assigned a $3.00 price target by HC Wainwright in a research note issued on Friday. The brokerage currently has a “buy” rating on the business services provider’s stock. HC Wainwright’s target price points to a potential upside of 180.37% from the company’s current price.
Several other analysts have also issued reports on IDXG. Maxim Group set a $3.00 price target on Interpace Diagnostics Group and gave the company a “buy” rating in a report on Thursday, July 19th. Zacks Investment Research raised Interpace Diagnostics Group from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a report on Wednesday, May 9th. LADENBURG THALM/SH SH started coverage on Interpace Diagnostics Group in a report on Friday, June 22nd. They set a “buy” rating and a $2.25 price target for the company. Finally, ValuEngine raised Interpace Diagnostics Group from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $2.75.
Interpace Diagnostics Group traded up $0.04, reaching $1.07, during mid-day trading on Friday, MarketBeat Ratings reports. 1,333,456 shares of the stock traded hands, compared to its average volume of 556,876. Interpace Diagnostics Group has a 12-month low of $0.72 and a 12-month high of $1.80.
Interpace Diagnostics Group (NASDAQ:IDXG) last posted its quarterly earnings data on Thursday, August 9th. The business services provider reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. The company had revenue of $5.50 million during the quarter, compared to analysts’ expectations of $4.80 million. Interpace Diagnostics Group had a negative return on equity of 34.55% and a negative net margin of 71.14%. research analysts anticipate that Interpace Diagnostics Group will post -0.37 earnings per share for the current year.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.